AR058082A1 - Formulacion en aerosol para la inhalacion de beta- agonistas - Google Patents

Formulacion en aerosol para la inhalacion de beta- agonistas

Info

Publication number
AR058082A1
AR058082A1 ARP060104405A ARP060104405A AR058082A1 AR 058082 A1 AR058082 A1 AR 058082A1 AR P060104405 A ARP060104405 A AR P060104405A AR P060104405 A ARP060104405 A AR P060104405A AR 058082 A1 AR058082 A1 AR 058082A1
Authority
AR
Argentina
Prior art keywords
alkyl
salts
enantiomers
halogen
possibly
Prior art date
Application number
ARP060104405A
Other languages
English (en)
Inventor
Michael Nowak
Barbara Niklaus-Humke
Kirsten Radau
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35241312&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR058082(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of AR058082A1 publication Critical patent/AR058082A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/468-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/12Aerosols; Foams
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Reivindicacion 1: Formulacion farmacologica que contiene como principio activo uno o varios compuestos de la formula general (1) en los que R1 es H, alquilo C1-4, O-alquilo C1-4 o halogeno; R2 es H, alquilo C1-4, O-alquilo C1-4 o halogeno; R3 es H, alquilo C1-4, O-alquilo C1-4, halogeno, OH, -O-alquilen C1-4-COOH u O-alquilen C1-4-COO-alquilo C1-4; X- es un anion de carga negativa simple, con preferencia un anion de carga negativa simple seleccionado el grupo compuesto por cloruro, bromuro, yoduro sulfato, fosfato, metansulfonato, nitrato, maleato, acetato, benzoato, citrato, salicilato, trifluoroacetato, fumarato, tartrato, oxalato, succinato, benzoato y p-toluensulfonato; eventualmente en forma de sus tautomeros, enantiomeros, mezclas de los enantiomeros, racematos, solvatos o hidratos; otro principio activo 2 seleccionado del grupo compuesto por sales de tiotropio, sales de oxitropio, sales de flutropio, sales de ipratropio, sales de glucopirronio y sales de trospio, eventualmente en forma de sus tautomeros, enantiomeros, mezclas de los enantiomeros, racematos, solvatos o hidratos; al menos un ácido farmacologicamente tolerable, eventualmente otros coadyuvantes y/o formadores de complejos farmacologicamente tolerables, y como disolvente agua, etanol o una mezcla de agua y etanol.
ARP060104405A 2005-10-10 2006-10-06 Formulacion en aerosol para la inhalacion de beta- agonistas AR058082A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05109376 2005-10-10

Publications (1)

Publication Number Publication Date
AR058082A1 true AR058082A1 (es) 2008-01-23

Family

ID=35241312

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060104405A AR058082A1 (es) 2005-10-10 2006-10-06 Formulacion en aerosol para la inhalacion de beta- agonistas

Country Status (31)

Country Link
US (3) US20070088030A1 (es)
EP (1) EP1940349B1 (es)
JP (1) JP2009511542A (es)
KR (1) KR20080059290A (es)
CN (1) CN101282712A (es)
AR (1) AR058082A1 (es)
AU (1) AU2006301330B9 (es)
BR (1) BRPI0617278A2 (es)
CA (1) CA2624786C (es)
CY (1) CY1120199T1 (es)
DK (1) DK1940349T3 (es)
EA (1) EA200800927A1 (es)
EC (1) ECSP088294A (es)
ES (1) ES2668364T3 (es)
HR (1) HRP20180713T1 (es)
HU (1) HUE039186T2 (es)
IL (1) IL190682A (es)
LT (1) LT1940349T (es)
MY (1) MY163503A (es)
NO (1) NO343363B1 (es)
NZ (1) NZ567545A (es)
PE (1) PE20070708A1 (es)
PL (1) PL1940349T3 (es)
PT (1) PT1940349T (es)
RS (1) RS57085B1 (es)
SI (1) SI1940349T1 (es)
TW (1) TWI389692B (es)
UA (1) UA99250C2 (es)
UY (1) UY29844A1 (es)
WO (1) WO2007042468A2 (es)
ZA (1) ZA200801390B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7056916B2 (en) * 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
US20050272726A1 (en) * 2004-04-22 2005-12-08 Boehringer Ingelheim International Gmbh Novel medicaments for the treatment of respiratory diseases
US20050255050A1 (en) * 2004-05-14 2005-11-17 Boehringer Ingelheim International Gmbh Powder formulations for inhalation, comprising enantiomerically pure beta agonists
US7220742B2 (en) * 2004-05-14 2007-05-22 Boehringer Ingelheim International Gmbh Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
US20050256115A1 (en) * 2004-05-14 2005-11-17 Boehringer Ingelheim International Gmbh Aerosol formulation for the inhalation of beta-agonists
MX2008001976A (es) * 2005-08-15 2008-03-25 Boehringer Ingelheim Int Procedimiento para la preparacion de betamimeticos.
WO2010057927A1 (en) * 2008-11-21 2010-05-27 Boehringer Ingelheim International Gmbh Aerosol formulation for the inhalation of beta agonists
EP2358350A1 (en) * 2008-11-21 2011-08-24 Boehringer Ingelheim International GmbH Aerosol formulation for the inhalation of beta agonists
GB201200525D0 (en) 2011-12-19 2012-02-29 Teva Branded Pharmaceutical Prod R & D Inc An inhalable medicament
WO2014016548A2 (en) 2012-07-27 2014-01-30 Cipla Limited Pharmaceutical composition
EP2906218B1 (en) 2012-10-09 2016-12-14 Boehringer Ingelheim International GmbH Beta-2-adrenoceptor agonist for the treatment of cough
US20140235627A1 (en) * 2012-12-21 2014-08-21 Boehringer Ingelheim International Gmbh ß2-ADRENOCEPTOR AGONIST FOR IMPROVEMENT OF EXERCISE TOLERANCE
US10034866B2 (en) 2014-06-19 2018-07-31 Teva Branded Pharmaceutical Products R&D, Inc. Inhalable medicament comprising tiotropium
BR112017020039A2 (pt) * 2015-05-18 2018-06-05 Glenmark Specialty S.A. composição farmacêutica, kit, método, processo para preparar uma composição e solução farmacêutica
CN110062625A (zh) 2016-12-12 2019-07-26 勃林格殷格翰国际有限公司 尼达尼布通过与奥达特罗共给予用于治疗间质性肺病的方法
CN115397417A (zh) * 2020-04-16 2022-11-25 广州谷森制药有限公司 含有噻托溴铵和奥达特罗的可吸入溶液制剂
CN114259481A (zh) * 2021-11-26 2022-04-01 南京华盖制药有限公司 一种奥达特罗复方吸入溶液

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3134590A1 (de) * 1981-09-01 1983-03-10 Boehringer Ingelheim KG, 6507 Ingelheim Neue benzo-heterocyclen
DE3931041C2 (de) 1989-09-16 2000-04-06 Boehringer Ingelheim Kg Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
KR100312357B1 (ko) * 1992-12-09 2002-04-24 데이비드 이. 프랭크하우저 안정화된약제의에어로졸용액제제
EE200200602A (et) * 2000-04-27 2004-04-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pikatoimelised beetamimeetikumid, meetod nende valmistamiseks ja nende kasutamine ravimitena
DE10216036A1 (de) 2002-04-11 2003-10-23 Boehringer Ingelheim Pharma Aerosolformulierung für die Inhalation enthaltend ein Tiotropiumsalz
DE10253282A1 (de) 2002-11-15 2004-05-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittel zur Behandlung von chronisch obstruktiver Lungenerkrankung
US7056916B2 (en) * 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
US7244728B2 (en) * 2004-03-17 2007-07-17 Boehringer Ingelheim International Gmbh Long acting betamimetics for the treatment of respiratory diseases
KR101287460B1 (ko) 2004-04-22 2013-07-23 베링거 인겔하임 인터내셔날 게엠베하 벤즈옥사진을 함유하는 호흡기 질환 치료용 약제학적배합물
US20050239778A1 (en) * 2004-04-22 2005-10-27 Boehringer Ingelheim International Gmbh Novel medicament combinations for the treatment of respiratory diseases
US20050272726A1 (en) * 2004-04-22 2005-12-08 Boehringer Ingelheim International Gmbh Novel medicaments for the treatment of respiratory diseases
US7220742B2 (en) * 2004-05-14 2007-05-22 Boehringer Ingelheim International Gmbh Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
US20050256115A1 (en) * 2004-05-14 2005-11-17 Boehringer Ingelheim International Gmbh Aerosol formulation for the inhalation of beta-agonists
US20050255050A1 (en) * 2004-05-14 2005-11-17 Boehringer Ingelheim International Gmbh Powder formulations for inhalation, comprising enantiomerically pure beta agonists

Also Published As

Publication number Publication date
MY163503A (en) 2017-09-15
ES2668364T3 (es) 2018-05-17
AU2006301330A1 (en) 2007-04-19
SI1940349T1 (en) 2018-05-31
US20070088030A1 (en) 2007-04-19
NO20080801L (no) 2008-04-29
EP1940349A2 (de) 2008-07-09
IL190682A (en) 2015-06-30
NZ567545A (en) 2011-07-29
RS57085B1 (sr) 2018-06-29
NO343363B1 (no) 2019-02-11
AU2006301330B9 (en) 2013-01-17
US20100009984A1 (en) 2010-01-14
CN101282712A (zh) 2008-10-08
PL1940349T3 (pl) 2018-07-31
ECSP088294A (es) 2008-04-28
HUE039186T2 (hu) 2018-12-28
IL190682A0 (en) 2008-11-03
CA2624786A1 (en) 2007-04-19
WO2007042468A2 (de) 2007-04-19
EA200800927A1 (ru) 2008-10-30
UA99250C2 (ru) 2012-08-10
PE20070708A1 (es) 2007-08-06
KR20080059290A (ko) 2008-06-26
CA2624786C (en) 2015-06-16
HRP20180713T1 (hr) 2018-06-15
DK1940349T3 (en) 2018-05-28
EP1940349B1 (de) 2018-02-14
ZA200801390B (en) 2009-01-28
JP2009511542A (ja) 2009-03-19
TW200730178A (en) 2007-08-16
WO2007042468A3 (de) 2007-08-02
BRPI0617278A2 (pt) 2011-07-19
CY1120199T1 (el) 2018-12-12
LT1940349T (lt) 2018-05-10
AU2006301330B2 (en) 2012-11-22
US20110190284A1 (en) 2011-08-04
UY29844A1 (es) 2007-05-31
TWI389692B (zh) 2013-03-21
PT1940349T (pt) 2018-04-30

Similar Documents

Publication Publication Date Title
AR058082A1 (es) Formulacion en aerosol para la inhalacion de beta- agonistas
CO6170341A2 (es) Formulacion de aerosol que contiene derivados de benzoxazin-3onas
CO6150123A2 (es) Formulacion de aerosol que contiene derivados de benzoxazin-3onas
AR049096A1 (es) Formulacion en aerosol sin gas propelente para la inhalacion de beta-agonistas
EA200600497A1 (ru) Композиция для аэрозольной ингаляции, содержащая антихолинергическое средство
ECSP034475A (es) Derivados de 4-fenil-piridin como antagonistas del receptor de neuroquinina-1
RU2006144123A (ru) Новые энантиомерночистые в-агонисты, способ их получения и их применение в качестве лекарственных средств
AR044719A1 (es) Derivados de fenilo y piridinilo, su uso, un proceso para prepararlos, y medicamentos que los contienen
AR035431A1 (es) 6,7,8,9-tetrahidro-5h-benzocicloheptenil aminas aciladas, un metodo para su sintesis, composiciones farmaceuticas y el uso de dichos compuestos para la fabricacion de medicamentos
HRP20120775T1 (hr) Antagonisti m3 muskarinskog acetilkolinskog receptora
AR037489A1 (es) Quinolinas sustituidas y proceso para su preparacion
AR066505A1 (es) Derivados de fenilaminobenceno sustituidos de utilidad para el tratamiento de trastornos y enfermedades hiperproliferativos asociados con actividad quinasa extracelular mediada por mitogenos
DE602006021539D1 (en) Morpholine als 5ht2c-agonisten
ES2759312T3 (es) Compuestos de aminocarbonilcarbamato
AR056198A1 (es) Un proceso para la fabricacion de una composicion farmaceutica tipo tableta
AR071799A1 (es) Derivados de hexafluoroisopropanol
AR039404A1 (es) Combinaciones de medicamentos que contienen compuestos heterociclicos y un agente anticolinergico. aerosol para su inhalacion
JP2010501022A5 (es)
AR049650A1 (es) Derivados 5-aril-1h-pirrol[2,3-b]piridin-3-carboxamida o acido 5-aril-1h-pirrol[2,3-b]piridin-3-carboxilico
JP2018529657A5 (es)
AR072802A1 (es) Derivados piperidinicos de esteres de acido bifenil-2-il-carbamico, antagonistas de receptores muscarinicos m3, composiciones farmaceuticas que los contienen y usos de los mismos para el tratamiento de trastornos digestivos,respiratorios y/o urinarios.
AR077301A1 (es) Derivados de 2-carboxamida-7-piperazinil-benzofurano como antagonistas de 5-ht1a y 5-ht1b
AR062476A1 (es) Beta - agonistas enentiomericamente puros, procedimientos para su preparacion y su uso como medicamentos
AR062477A1 (es) Formulacion aerosol para la inhalacion de beta - agonistas
AR055597A1 (es) Uso de sales de tiotripio en el tratamiento del asma persistente severa

Legal Events

Date Code Title Description
FC Refusal